Comparative Pharmacology
Head-to-head clinical analysis: K 10 versus KLOROMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 10 versus KLOROMIN.
K+10 vs KLOROMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
KLOROMIN is a potassium-sparing diuretic that acts by antagonizing aldosterone in the distal renal tubules, inhibiting sodium reabsorption and potassium excretion.
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
1 g IV every 6 hours; infuse over 30 minutes.
None Documented
None Documented
Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extends to 20-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 50 hours in severe impairment (CrCl <30 mL/min).
Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment.
Primarily renal (60-70% as unchanged drug, 10-20% as glucuronide conjugate), biliary/fecal (10-15% as metabolites).
Category C
Category C
Potassium Supplement
Potassium Supplement